Pfizer has abandoned its research work on drugs that could treat Alzheimer’s and Parkinson’s diseases. The big pharmaceutical’s decision comes as a big blow to tens of millions of people suffering from the said diseases not only in the United States but also around the world.
Pfizer, one of the world’s largest pharma, said that the move is part of the company’s refocusing on areas where its pipeline and scientific expertise is the strongest. It will reallocate its funding from the neuroscience discovery and early development programs across its portfolio, Reuters reported.
The company provided a robust investment in research and development of a cure for Alzheimer’s and Parkinson’s over the past years. It joined GlaxoSmithKline and Eli Lilly in the Dementia Discovery Fund launched in 2015 to develop treatments for Alzheimer’s.
Unfortunately, Pfizer sees that its efforts in the past years “were not going to deliver the impactful medical advances for patients that we had aspired to achieve,” said Mikael Dolsten, Pfizer worldwide research and development president, via Newsweek.
Expensive and complicated clinical trials due to the difference in the development of Parkinson’s and Alzheimer’s for every person led to the company’s unsuccessful endeavors. In 2012, Pfizer wrote off $725 million after its dimebon drug failed to aid Alzheimer’s patients in a phase-three trial. It has funded 99 trials of 24 potential Alzheimer’s drugs in the past 20 years, but only one, the Aricept, has received approval.
Reactions of persons afflicted
Over 10 million people are living with Parkinson’s disease, and 47 million people suffer from Alzheimer’s and dementia around the world. Big pharmaceutical companies like Pfizer play a huge role in helping to advance the development of treatments that many patients depend on to improve the quality of their lives. This is why Pfizer’s retreat disappoints many, particularly those who have Alzheimer’s and Parkinson’s.
“As a 49 year old living with Parkinson’s disease, I think Pfizer’s decision is a disappointment… Any one of us can get these life-changing diseases. At the very least, Pfizer should think about the human element in its decisions,” Allan Hugh Cole Jr., a professor at the University of Texas, who is living with Parkinson’s disease, wrote on Fortune.
“It’s very difficult to reconcile statements like ‘most value to shareholders’ from Pfizer when you’re 53 and living with a terminal disease like Alzheimer’s,” Jeff Borghoff, a former software developer, told Newsweek.
A possible trend
Parkinson’s Foundation chief scientific officer James Beck said that with Pfizer’s exit from the neurological diseases research, there is a fear that it might become a trend among other large companies. If more of the largest pharmaceuticals also decided to abandon their neuroscience research, other companies might follow through. While there are private foundations and government initiatives to keep the research and development on treatments for neurological diseases going, big pharmaceuticals are instrumental in getting those drugs in the market, he added.
Meanwhile, Pfizer has promised that it will create a new venture fund to invest in neuroscience research project.
Get lower hotel prices, better services with these insider tips
There are ways you can get better hotel prices and services when you travel. Take these tips from an insider...
What to do before investing in foreclosed property with your IRA
Buying a foreclosed property is different than acquiring one through normal channels, and so buyers need to have extra knowledge.
Car rental industry increases transparency that could end surcharges
The car rental industry is slowly changing as companies are providing more price transparency for customers.
How singles should plan for retirement
About 56 percent of Americans have less than $10,000 when they retire. Follow these tips if you want to have...
India’s tech scene brings in foreign investments
India's economy is growing fast today, and it's ready to take in new foreign investments. The IBM-HCL Technologies partnership is...
Featured4 days ago
CEOs Fishkin and Ramsay: From financial burdens to million-dollar companies
Destinations4 days ago
Millennials with money escape to Mexico’s Bohemian luxury
Sponsored3 days ago
Cannabis retailer Choom secures leadership position with Ontario expansion
Business5 days ago
Disney continues quest to buy Fox, Brazilian regulators raise concerns
Sponsored4 days ago
The Alkaline Water Co. begins trading on NASDAQ today
Business5 days ago
IoT and LaaS mean stronger growth for LED market
Crowdfunding4 days ago
Why female and minority founders should look to crowdfunding
Crowdfunding4 days ago
Dispelling misconceptions about startup accelerators and their role in the startup industry